These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8879478)

  • 21. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
    Bailey JE; Papadopoulos A; Seddon K; Nutt DJ
    J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A kind of D-amino acid oxidase inhibitor, sodium benzoate, might relieve panic symptoms in a first-episode, drug-naïve panic-disorder patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E7-8. PubMed ID: 23686042
    [No Abstract]   [Full Text] [Related]  

  • 24. Benzodiazepines and anxiety sensitivity in panic disorder.
    Fava GA; Grandi S; Belluardo P; Savron G; Raffi AR; Conti S; Saviotti FM
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1163-8. PubMed ID: 7846286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partitioning psychological and physical sources of transport-related stress in young cattle.
    Jacobson LH; Cook CJ
    Vet J; 1998 Mar; 155(2):205-8. PubMed ID: 9564276
    [No Abstract]   [Full Text] [Related]  

  • 26. [Panic disorder].
    Heinzl S
    Med Monatsschr Pharm; 1996 Mar; 19(3):79-80. PubMed ID: 8868966
    [No Abstract]   [Full Text] [Related]  

  • 27. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
    Maron E; Tõru I; Vasar V; Shlik J
    J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
    Honore P; Buritova J; Fournié-Zaluski MC; Roques BP; Besson JM
    J Pharmacol Exp Ther; 1997 Apr; 281(1):208-17. PubMed ID: 9103499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings.
    Sramek JJ; Kramer MS; Reines SA; Cutler NR
    Anxiety; 1994-1995; 1(3):141-3. PubMed ID: 9160564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neurochemical effects of anxiolytic drugs are dependent on rearing conditions in Fawn-Hooded rats.
    Lodge DJ; Lawrence AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):451-8. PubMed ID: 12691780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 33. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
    J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growing placebo response rate: the problem in recent therapeutic trials?
    Uhlenhuth EH; Matuzas W; Warner TD; Thompson PM
    Psychopharmacol Bull; 1997; 33(1):31-9. PubMed ID: 9133749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome.
    Wilson J; Little HJ
    Pharmacol Biochem Behav; 1998 Apr; 59(4):967-73. PubMed ID: 9586857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Startle reflex modulation and autonomic responding during anxious apprehension in panic disorder patients.
    Melzig CA; Weike AI; Zimmermann J; Hamm AO
    Psychophysiology; 2007 Nov; 44(6):846-54. PubMed ID: 17640268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988.
    Singh L; Field MJ; Vass CA; Hughes J; Woodruff GN
    Br J Pharmacol; 1992 Jan; 105(1):8-10. PubMed ID: 1350747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI-988.
    Romani R; Howes LG; Morris DL
    Clin Exp Pharmacol Physiol; 1996 May; 23(5):438-40. PubMed ID: 8713686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCK-antagonists in a rat exposed to acute stress: implication for anxiety associated with post-traumatic stress disorder.
    Cohen H; Kaplan Z; Kotler M
    Depress Anxiety; 1999; 10(1):8-17. PubMed ID: 10499184
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.